Tag: Cell Signaling and Communication

Editors’ Picks, January 2025: Evolutionary Insights Into Cancer, Impact of Nicotine Levels in E-cigarettes, and More

As winter marches on, let’s dive into the cool articles highlighted this month by the editors of the AACR journals. Grab a blanket and keep reading to learn how nicotine levels in e-cigarettes impact exposure to various toxins, why certain species are more likely to develop cancer, and results from a first-in-human trial evaluating a… Continue reading Editors’ Picks, January 2025: Evolutionary Insights Into Cancer, Impact of Nicotine Levels in E-cigarettes, and More

TWiV 1186: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin and co-host Vincent Racaniello lament about the public changes from withdrawing from the WHO to health and scientific communication pauses by the Trump Administration after a brief discussion of Marburg in Tanzania and mpox in England before reviewing cats and bird flu, the recent statistics on RSV, influenza… Continue reading TWiV 1186: Clinical update with Dr. Daniel Griffin

Synapse-to-Nucleus ERK->CREB Transcriptional Signaling Requires Dendrite-to-Soma Ca2+ Propagation Mediated by L-Type Voltage-Gated Ca2+ Channels

The cAMP-response element–binding protein (CREB) transcription factor controls the expression of the neuronal immediate early genes c-fos, Arc, and Bdnf and is essential for long-lasting synaptic plasticity underlying learning and memory. Despite this critical role, there is still ongoing debate regarding the synaptic excitation–transcription (E–T) coupling mechanisms mediating CREB activation in the nucleus. Here we… Continue reading Synapse-to-Nucleus ERK->CREB Transcriptional Signaling Requires Dendrite-to-Soma Ca2+ Propagation Mediated by L-Type Voltage-Gated Ca2+ Channels

RPRD1B’s direct interaction with phosphorylated RNA Polymerase II regulates polyadenylation of cell cycle genes and drives cancer progression

RNA Polymerase II (Pol II) regulates eukaryotic gene expression through dynamic phosphorylation of its C-terminal domain (CTD). Phosphorylation at Ser2 and Thr4 on the CTD is crucial for RNA 3’ end processing and facilitating the recruitment of cleavage and termination factors. However, the transcriptional roles of most CTD-binding proteins remain poorly understood. In this study,… Continue reading RPRD1B’s direct interaction with phosphorylated RNA Polymerase II regulates polyadenylation of cell cycle genes and drives cancer progression

RPRD1B’s direct interaction with phosphorylated RNA polymerase II regulates polyadenylation of cell cycle genes and drives cancer progression

RNA polymerase II (Pol II) regulates eukaryotic gene expression through dynamic phosphorylation of its C-terminal domain (CTD). Phosphorylation at Ser2 and Thr4 on the CTD is crucial for RNA 3′ end processing and facilitating the recruitment of cleavage and termination factors. However, the transcriptional roles of most CTD-binding proteins remain poorly understood. In this study,… Continue reading RPRD1B’s direct interaction with phosphorylated RNA polymerase II regulates polyadenylation of cell cycle genes and drives cancer progression

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

Purpose BMS-986299 is a first-in-class, NOD-, LRR-, and pyrin-domain containing-3 (NLRP3) inflammasome agonist enhancing adaptive immune and T-cell memory responses. Materials and methods This was a phase-I (NCT03444753) study that assessed the safety and tolerability of intra-tumoral BMS-986299 monotherapy (part 1A) and in combination (part 1B) with nivolumab, and ipilimumab in advanced solid tumors. Reported… Continue reading Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

Clinical Trials Are Testing Ways to Prevent Breast Cancer

Higher screening rates along with treatment advances have reduced breast cancer deaths by 42% in recent decades. Still, it remains the second deadliest cancer among women in the United States, with over 40,000 expected to die of the disease last year. And for the almost 4 million women living with breast cancer, the physical and mental… Continue reading Clinical Trials Are Testing Ways to Prevent Breast Cancer